Coprescription of Tamoxifen and Medications That Inhibit CYP2D6

Evidence has emerged that the clinical benefit of tamoxifen is related to the functional status of the hepatic metabolizing enzyme cytochrome P450 2D6 (CYP2D6). CYP2D6 is the key enzyme responsible for the generation of the potent tamoxifen metabolite, endoxifen. Multiple studies have examined the r...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Sideras, Kostandinos, Ingle, James N., Ames, Matthew M., Loprinzi, Charles L., Mrazek, David P., Black, John L., Weinshilboum, Richard M., Hawse, John R., Spelsberg, Thomas C., Goetz, Matthew P.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2010
Soggetti:
Review Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2881853/
https://ncbi.nlm.nih.gov/pubmed/20439629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.23.8931
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi